The UCLA Neuro-oncology Program conducts extensive translational and clinical research focused on individualizing treatments to extend and improve the lives of patients with primary brain tumors. The program faculty members often collaborate with other investigators in the UCLA Brain Tumor Center and are part of the brain cancer SPORE.

Basic and Translational Research:
UCLA Brain Tumor Center Research

Additional Information - Neuro-Oncology Program:
Brain Tumor & Brain Cancer Treatment
Neuro-Oncology Program
The Lai Lab


Clinical Trials

Neuro-Oncology clinical trials include advanced treatment modalities for brain cancer including targeted therapies, viral therapies, and immunotherapies. Other clinical trials include studies in tumor imaging, quality of care, and neurocognition in collaboration with other researchers at UCLA Health.

For questions on clinical trials, contact:
Emese Filka
Clinical Trial Coordinator
310-794-3521

You may find more information on the following clinical trials offered by our program at ClinicalTrials.gov

UCLA - IRB NumberStudy AgentTargeted Pathology DiagnosisTrial Phase
#14-000514Lapatinib with SurgeryRecurrent High-Grade GliomaEarly Phase
#14-000800MLN0128 with SurgeryPreoperative Recurrent Glioblastoma (GBM)                                          Pilot Study
#15-001667ACP-196Recurrent GBMPhase 1b/2
#16-000207Nivolumab vs Temozolomide, with RTNewly Diagnosed GBMPhase 3
#16-000365Temozolomide plus Radiation  Therapy (RT) Combined with NivolumabNewly Diagnosed GBMPhase 2
#16-000464IL-7 (CYT107)High Grade GliomasPilot Study
#16-000576DNX-2401 with Pembrolizumab1st or 2nd Recurrent GBM or GliosarcomaPhase 2
#16-000649ABT-414 with Concurrent Chemoradiation and Adjuvant TemozolomideNewly Diagnosed GBMPhase 2b/3
#16-001865PembrolizumabRecurrent Malignant GliomaPilot Study
#16-001874AbemaciclibRecurrent GBMPhase 2
#17-000338Avelumab with HFRTRecurrent GBM transformed from low grade gliomaPhase 2
#17-000756PT2385Recurrent GBMPhase 2
#17-000758Anti-LAG-3 or Anti-CD137 in Combination with Anti-PD-1Recurrent GBMPhase 1
#17-000794DSP-7888 with BevacizumabRecurrent GBMPhase 2
#17-000998BGB-290 with Temozolomide and/or RTNewly Diagnosed GBM or 1st Recurrent GBMPhase 1b/2
#17-001423AMG596Newly Diagnosed GBM or Recurrent GBMPhase 1
#17-001719AG120 or AG881, with surgeryRecurrent Grade 2 or 3 Low Grade GliomaPhase 1

Giving: Your gift to the UCLA Neuro-Oncology Program makes a difference.